Are you a Health Professional? Jump over to the doctors only platform. Click Here

Vaccine for Croup Shows Promise in Adults

Print Friendly, PDF & Email

n experimental vaccine for the common coughing disease croup has shown promise in an initial trial of healthy adults, a forerunner to studies in children–the target population for the vaccine.. The vaccine is inhaled through the nose rather than injected — an added benefit for kids.

n experimental vaccine for the common coughing disease croup has shown promise in an initial trial of healthy adults, a forerunner to studies in children–the target population for the vaccine.. The vaccine is inhaled through the nose rather than injected — an added benefit for kids.Human parainfluenza virus-type 1 (hPIV-1) is the most common cause of croup, sending nearly 30,000 children to US hospitals each year, Memphis, Tennessee-based researchers note in the medical journal Vaccine. There currently is no vaccine available for hPIV-1.In an FDA-approved trial, Dr. Karen S. Slobod from St. Jude Children’s Research Hospital and colleagues tested a mouse virus called SeV as a vaccine for the closely related hPIV-1 in nine healthy adults.As hoped, the vaccine induced an immune response against hPIV-1 in many of the subjects. Moreover, each of the three test doses of SeV was “uniformly well-tolerated,” the authors note. SeV caused no respiratory or allergic symptoms and was not recovered from the nasal passages of the subjects.This study “demonstrates the potential for SeV to serve as a…vaccine for hPIV-1,” Slobod and colleagues write.”We are hopeful that (SeV) will prove a safe, effective and painless vaccine against the very common croup virus,” Slobod told Reuters Health.”Based on our previous pre-clinical studies, and the encouraging safety results from the current human trial, we are very optimistic about our upcoming pediatric studies,” she added.”These studies will also focus on demonstrating safety and, among young children who are naïve to the croup virus, evaluating the immune response to SeV.”(SOURCE: Reuters, Vaccine 2004.)

Print Friendly, PDF & Email

Dates

Posted On: 3 September, 2004
Modified On: 5 December, 2013

Tags



Created by: myVMC